PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience
PARP inhibitors may be considered for patients with advanced pancreatic cancer harboring pathogenic alterations of <i>BRCA</i> who cannot tolerate standard chemotherapy. Maintenance PARPis can be considered in selected patients with non-<i>BRCA</i>/non-<i>PALB2</i> HRR mutations.
Authors
- Sal Bottiglieri
- Darcy K. Berry (ORCID: https://orcid.org/0000-0003-2585-3926)
- J. Kevin Hicks (ORCID: https://orcid.org/0000-0003-2314-0164)
- Katelyn Sommerer (ORCID: https://orcid.org/0000-0003-3029-644X)
- Ruoyu Miao (ORCID: https://orcid.org/0000-0003-4286-5742)
- Alex Del Cueto
- Anand Shah (ORCID: https://orcid.org/0000-0002-9217-9065)
- Kirsten Blue
- Dae Won Kim (ORCID: https://orcid.org/0000-0001-8785-4508)
Institutions
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-11
- DOI
- https://doi.org/10.3390/cancers16203447
- Citations
- 5
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.41